Neuronetics, Inc. (STIM)
Automate Your Wheel Strategy on STIM
With Tiblio's Option Bot, you can configure your own wheel strategy including STIM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STIM
- Rev/Share 1.4553
- Book/Share 0.6431
- PB 6.8483
- Debt/Equity 2.3282
- CurrentRatio 2.4423
- ROIC -0.3172
- MktCap 259990185.0
- FreeCF/Share -0.6066
- PFCF -6.9731
- PE -5.0574
- Debt/Assets 0.5813
- DivYield 0
- ROE -2.0889
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair William Plovanic - Canaccord Genuity Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2025 Financial and Operating Results Conference Call.
Read More
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Neuronetics (STIM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago.
Read More
Neuronetics Reports First Quarter 2025 Financial and Operating Results
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025.
Read More
Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating Results Conference Call.
Read More
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company.
Read More
About Neuronetics, Inc. (STIM)
- IPO Date 2018-06-28
- Website https://www.neurostar.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Keith J. Sullivan
- Employees 716